The HPV vaccine that is now available in Hangzhou targets males aged 9 to 26. [Photo/tidenews.com.cn]

Hangzhou – capital of East China's Zhejiang province – administered its first vaccine approved for male use for HPV or human papillomavirus, a viral infection that commonly causes skin or mucous membrane growths or warts and can cause cancer.

The vaccine, targeting males aged 9 to 26, prevents HPV-related conditions like anal cancer and genital warts.

Zhu, 24, was the first recipient at the Sandun community health center, prioritizing his and his partner's health.

Experts are emphasizing the vaccine's importance in preventing HPV-linked cancers in both men and women. Professor Wang Hui of Zhejiang University underscored the male vaccination's role in herd immunity and in helping to achieve the World Health Organization's 2030 goal to eliminate cervical cancer.

Health officials are encouraging men to get vaccinated – highlighting the vaccine's proven safety and effectiveness. Hangzhou is offering easy access to vaccination appointments through clinics, apps and online platforms.

A 24-year-old man surnamed Zhu is the first recipient in Hangzhou. [Photo/tidenews.com.cn]